Progenics Pharmaceuticals (PGNX) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 04, 2020
Document Information [Line Items]
Entity Registrant Name	Progenics Pharmaceuticals Inc
Entity Central Index Key	0000835887
Trading Symbol	pgnx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		86,596,633
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common stock, par value $0.0013 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 29,531	$ 42,049
Accounts receivable, net	6,190	15,976
Other current assets	4,825	5,707
Total current assets	40,546	63,732
Property and equipment, net	14,673	11,688
Intangible assets, net	6,547	6,823
Goodwill	17,847	17,847
Operating right-of-use lease assets	13,279	13,493
Other assets	5,452	5,887
Total assets	98,344	119,470
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	2,860	1,249
Accrued expenses	8,383	13,103
Current portion of debt, net	7,240	7,117
Operating lease liabilities	616	599
Total current liabilities	19,099	22,068
Long-term debt, net	30,166	31,910
Operating lease liabilities	14,832	15,005
Contingent consideration liability	3,600	3,900
Deferred tax liability	34	34
Total liabilities	67,731	72,917
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value Authorized - 20,000 shares; issued and outstanding - none	0	0
Common stock, $0.0013 par value Authorized - 160,000 shares; issued - 86,796 shares in 2020 and 86,760 shares in 2019	113	113
Additional paid-in capital	728,129	727,089
Treasury stock at cost, 200 shares of common stock	(2,741)	(2,741)
Accumulated other comprehensive loss	(327)	(148)
Accumulated deficit	(694,561)	(677,760)
Total stockholders’ equity	30,613	46,553
Total liabilities and stockholders’ equity	$ 98,344	$ 119,470

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000	20,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0013	$ 0.0013
Common stock, shares authorized (in shares)	160,000	160,000
Common stock, shares issued (in shares)	86,796	86,760
Treasury stock at cost, shares (in shares)	200	200

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Revenue	$ 6,248	$ 4,281
Operating expenses:
Cost of goods sold	1,558
Research and development	10,367	12,392
Selling, general and administrative	10,509	9,224
Change in contingent consideration liability	(300)	900
Total operating expenses	22,134	22,516
Operating loss	(15,886)	(18,235)
Other (expense) income:
Interest (expense) income and other income, net	(915)	(500)
Total other (expense) income	(915)	(500)
Net loss	$ (16,801)	$ (18,735)
Net loss per share - basic and diluted (in dollars per share)	$ (0.19)	$ (0.22)
Weighted-average shares - basic and diluted (in shares)	86,582	84,542
Product [Member]
Revenues:
Revenue	$ 1,359
Royalty [Member]
Revenues:
Revenue	4,789	4,161
License and Other [Member]
Revenues:
Revenue	$ 100	$ 120

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net loss	$ (16,801)	$ (18,735)
Other comprehensive loss:
Foreign currency translation adjustments	(179)	(42)
Comprehensive loss	$ (16,980)	$ (18,777)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2018	84,742,000				(200,000)
Balance at Dec. 31, 2018	$ 110	$ 713,019	$ (609,208)	$ (105)	$ (2,741)	$ 101,075
Net loss			(18,735)			(18,735)
Foreign currency translation adjustments				(42)		(42)
Stock-based compensation expense		1,077				$ 1,077
Exercise of stock options (in shares)						0
Balance (in shares) at Mar. 31, 2019	84,742,000				(200,000)
Balance at Mar. 31, 2019	$ 110	714,096	(627,943)	(147)	$ (2,741)	$ 83,375
Balance (in shares) at Dec. 31, 2019	86,760,000				(200,000)
Balance at Dec. 31, 2019	$ 113	727,089	(677,760)	(148)	$ (2,741)	46,553
Net loss			(16,801)			(16,801)
Foreign currency translation adjustments				(179)		(179)
Stock-based compensation expense		878				$ 878
Exercise of stock options (in shares)	36,000					36,000
Exercise of stock options		162				$ 162
Balance (in shares) at Mar. 31, 2020	86,796,000				(200,000)
Balance at Mar. 31, 2020	$ 113	$ 728,129	$ (694,561)	$ (327)	$ (2,741)	$ 30,613

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (16,801)	$ (18,735)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	878	1,077
Depreciation and amortization	742	557
Non-cash interest expense	61	71
Other		11
Change in fair value of contingent consideration liability	(300)	900
Changes in assets and liabilities:
Accounts receivable	9,786	(1,136)
Other current assets	968	(447)
Other assets	286	146
Accounts payable	1,618	124
Accrued expenses	(4,888)	(991)
Other current liabilities	217	18
Other liabilities	(174)	(114)
Net cash used in operating activities	(7,607)	(18,519)
Cash flows from investing activities:
Acquisition of AZEDRA manufacturing assets		(8,000)
Purchases of property and equipment	(3,553)	(491)
Net cash used in investing activities	(3,553)	(8,491)
Cash flows from financing activities:
Repayment of debt	(1,682)	(1,037)
Proceeds from exercise of stock options	162
Net cash used in financing activities	(1,520)	(1,037)
Effect of currency rate changes on cash, cash equivalents and restricted cash	(201)	(46)
Net decrease in cash, cash equivalents, and restricted cash	(12,881)	(28,093)
Cash, cash equivalents, and restricted cash at beginning of period	45,065	139,220
Cash, cash equivalents, and restricted cash at end of period	32,184	111,127
Supplemental disclosure of cash flow information
Cash paid for interest	939	1,077
Cash, cash equivalents and restricted cash information
Cash and cash equivalents at beginning of period	42,049	137,686
Restricted cash included in long-term assets at the beginning of period	3,016	1,534
Cash, cash equivalents, and restricted cash at beginning of period	45,065	139,220
Cash and cash equivalents at end of period	29,531	109,587
Restricted cash included in long-term assets at the end of period	2,653	1,540
Cash, cash equivalents, and restricted cash at end of period	$ 32,184	$ 111,127

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Business Progenics Pharmaceuticals, Inc. (and its subsidiaries collectively the “Company,” “Progenics”, “we”, or “us”) is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer. Our recent progress includes the enrollment completion of our pivotal phase 3 ® 1095 1404 Our current principal sources of revenue are AZEDRA sales, royalties, and development and commercial milestones from strategic partnerships. Royalty and further milestone payments from Bausch or Bayer depend on success in development and commercialization of RELISTOR and our PSMA-TTC, respectively, which is dependent on many factors, such as Bausch or Bayer’s efforts, decisions by the FDA and other regulatory bodies, competition from drugs for the same or similar indications, and the outcome of clinical and other testing of the licensed products. We commenced principal operations in 1988, 1997, Pending Merger with Lantheus Holdings, Inc. On February 20, 2020, October 1, 2019. 0.31 0.2502 one two no 19.9% 40% 35% On April 2, 2020, April 28, 2020 June 16, 2020. 19 second 2020, On April 14, 2020, $1.3 September 18, 2019 8 Table of Contents In addition, on April 14, 2020, AZEDRA AZEDRA is the first 12 First quarter sales of AZEDRA totaled approximately $1.4 March 31, 2020. 19 19 19 PyL We recently completed two third 2020. Several abstracts pertaining to PyL were recently published in the Journal of Urology, including the results of the Phase 3 84.8% 87.0% three 95% 77.8% 80.4% 1095 Following the removal of the import alert on Centre for Probe Development & Commercialization (CPDC), we have initiated eleven six 2 Progenics’1095 19 2 131 1095 1095 19 9 Table of Contents Liquidity The Company is not no March 31, 2020 $694.6 19 third At March 31, 2020, $29.5 $12.5 $42.0 December 31, 2019. February 20, 2020, March 15, 2020, May 1, 2020 $10 September 30, 2020 one third 9.5% Consistent with regular practice for a growth-stage pharmaceutical or biotechnology company, and as we have done in the past, we anticipate the need, and are exploring options for, additional financing in order to meet our cash requirements if the proposed merger with Lantheus Holdings is not no one one 10 not Basis of Presentation Our unaudited condensed consolidated financial statements have been prepared in accordance with applicable presentation requirements, and accordingly, do not not Our unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in our Annual Report on Form 10 December 31, 2019. not Principles of Consolidation The condensed consolidated financial statements include the accounts of Progenics as well as its wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. 10 Table of Contents Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may Revenue Recognition We recognize revenue when our customers obtain control of the promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To account for our revenue arrangements, we perform the following five For contracts determined to be within the scope of ASU 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 606” not The transaction price is then determined and allocated to the identified performance obligations in proportion to their estimated fair value, which requires significant judgment. Variable consideration, which is estimated using the expected value method or the most likely amount method, is included in the transaction price only if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not For arrangements that include development, regulatory or sales milestone payments, we evaluate whether the milestones are probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The following table summarizes our revenue streams from contracts with customers for the three March 31, 2020 2019 Three months ended March 31, 2020 2019 Product sales $ 1,359 $ - Royalty income 4,789 4,161 License and other revenue 100 120 Total revenue $ 6,248 $ 4,281 P roduct sales 60 Royalty income 11 Table of Contents License and o ther revenue not We had receivable contract balances of $6.2 $16.0 March 31, 2020 December 31, 2019, December 31, 2019 Note 5. Restricted Cash Restricted cash included in long-term assets of $2.7 $3.0 March 31, 2020 December 31, 2019, 617 Foreign Currency Translation Our international subsidiaries generally consider their respective local currency to be their functional currency. Assets and liabilities of these international subsidiaries are translated into U.S. dollars at quarter-end exchange rates and revenues and expenses are translated at average exchange rates during the quarter and year-to-date period. Foreign currency translation adjustments for the reported periods are included in accumulated other comprehensive loss in our condensed consolidated statements of comprehensive loss, and the cumulative effect is included in the stockholders’ equity section of our condensed consolidated balance sheets. Realized gains and losses denominated in foreign currencies are recorded in operating expenses in our condensed consolidated statements of operations and were not three March 31, 2020 2019. Leases We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not not may The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU lease assets are reported in other noncurrent assets on our condensed consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in research and development and selling, general and administrative expenses on our condensed consolidated statements of operations. We do not twelve Property and Equipment Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $4.3 $3.8 March 31, 2020 December 31, 2019, March 31, December 31, 2020 2019 Machinery and equipment $ 6,809 $ 5,204 Leasehold improvements 3,621 3,204 Computer equipment 710 691 Furniture and fixtures 908 908 Construction in progress 6,884 5,475 Property and equipment, gross 18,932 15,482 Less - accumulated depreciation (4,259 ) (3,794 ) Property and equipment, net $ 14,673 $ 11,688 12 Table of Contents

Note 2 - New Accounting Pronoun

Note 2 - New Accounting Pronouncements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Note 2. Recently Adopted In August 2018, 2018 13 2018 13” Fair Value Measurement - Disclosure Framework (Topic 820 January 1, 2020. not Recently Issued In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 November 2018, 2018 19, Codification Improvements to Topic 326, April 2019, 2019 04, Codification Improvements to Topic 326, 815, 825, 2016 13. May 2019, 2019 05, Financial Instruments—Credit Losses (Topic 326 may 2016 13 November 2019, 2019 10, Financial Instruments—Credit Losses (Topic 326 815 842 one two 2016 13 December 15, 2019 December 15, 2022 In December 2019, 2019 12, Income Taxes (Topic 740 740. 740 December 15, 2020. December 15, 2021, December 15, 2022.

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 3 . Net Loss Per Share Our basic net loss per share amounts have been computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For the three March 31, 2020 2019, not The calculations of net loss per share, basic and diluted, are as follows (amounts in thousands, except per share data): Weighted-Average Shares Net Loss Outstanding Per Share (Numerator) (Denominator) Amount Three months ended March 31, 2020 Basic and diluted $ (16,801 ) 86,582 $ (0.19 ) Three months ended March 31, 2019 Basic and diluted $ (18,735 ) 84,542 $ (0.22 ) The following table summarizes anti-dilutive common shares or common shares where performance conditions have not Three Months Ended March 31, 2020 2019 Stock options 6,597 6,522 Contingent consideration liability (1) 947 2,565 Total securities excluded 7,544 9,087 ___________________________________ ( 1

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4 . Fair Value Measurements To estimate the fair values of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three ● Level 1 ● Level 2 1 ● Level 3 The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may We believe the carrying amounts of our cash equivalents, restricted cash, accounts receivable, other current assets, other assets, accounts payable and accrued expenses approximated their fair values as of March 31, 2020 December 31, 2019. We record the contingent consideration liability resulting from our acquisition of MIP at fair value in accordance with Accounting Standards Codification (“ASC”) 820 820, Fair Value Measurement The following tables summarize each major class of our financial assets and liabilities measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy (in thousands): Fair Value Measurements at March 31, 2020 Quoted Prices in Significant Other Significant Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs March 31, 2020 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 20,744 $ 20,744 $ - $ - Total assets $ 20,744 $ 20,744 $ - $ - Liabilities: Contingent consideration liability $ 3,600 $ - $ - $ 3,600 Total liabilities $ 3,600 $ - $ - $ 3,600 Fair Value Measurements at December 31, 2019 Quoted Prices in Active Significant Other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2019 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 35,775 $ 35,775 $ - $ - Total assets $ 35,775 $ 35,775 $ - $ - Liabilities: Contingent consideration liability $ 3,900 $ - $ - $ 3,900 Total liabilities $ 3,900 $ - $ - $ 3,900 The contingent consideration liability of $3.6 March 31, 2020 Milestone payments due upon first Program Consideration Form of Payment 1095 5,000 Cash or Progenics common stock 1404 9,984 Cash or Progenics common stock or cash in the case of license revenue $ 14,984 Net sales milestone payments due upon first Consideration Form of Payment at Progenics' Option $30 million $ 5,000 Cash or Progenics common stock $60 million 5,000 Cash or Progenics common stock $100 million 10,000 Cash or Progenics common stock $250 million 20,000 Cash or Progenics common stock $500 million 30,000 Cash or Progenics common stock $ 70,000 We consider this liability a Level 3 one Significant changes in any of the probabilities of success or the probabilities as to the periods in which milestones will be achieved would result in a significantly higher or lower fair value measurement. We record the contingent consideration liability at fair value with changes in estimated fair values recorded in change in contingent consideration liability in our condensed consolidated statements of operations. The following table summarizes quantitative information and assumptions pertaining to the fair value measurement of the Level 3 March 31, 2020 December 31, 2019 ( $0.3 three March 31, 2020 Fair Value at March 31, 2020 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: 1095 commercialization $ 400 Probability adjusted discounted Probability of success 18% cash flow model Period of expected milestone achievement 2027 Discount rate 10% 1404 commercialization 200 Probability adjusted discounted Probability of success 43% cash flow model Period of expected milestone achievement 2023 - 2035 Discount rate 10% Net sales targets 3,000 Monte-Carlo simulation Probability of success 18% - 90% Discount rate 10% Total $ 3,600 Fair Value at December 31, 2019 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: 1095 commercialization $ 500 Probability adjusted discounted Probability of success 18% cash flow model Period of expected milestone achievement 2026 Discount rate 10% 1404 commercialization 300 Probability adjusted discounted Probability of success 43% cash flow model Period of expected milestone achievement 2022 - 2035 Discount rate 10% Net sales targets 3,100 Monte-Carlo simulation Probability of success 18% - 90% Discount rate 10% Total $ 3,900 For those financial instruments with significant Level 3 Liability - Contingent Consideration Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 3,900 $ 11,000 Fair value change included in net loss (300 ) 900 Balance at end of period $ 3,600 $ 11,900 Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period $ (300 ) $ 900

Note 5 - Accounts Receivable

Note 5 - Accounts Receivable	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 5 . Accounts Receivable Our accounts receivable represents amounts due to us from royalties, collaborators, AZEDRA product sales and, to a small extent, sales of research reagents, and consisted of the following at March 31, 2020 December 31, 2019 ( March 31, December 31, 2020 2019 Royalties $ 4,789 $ 4,304 Product sales, license and other 1,401 11,672 Accounts receivable, net $ 6,190 $ 15,976

Note 6 - Goodwill, In-process R

Note 6 - Goodwill, In-process Research and Development and Other Intangible Assets	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 6 . Goodwill, In-Process Research and Development and Other Intangible Assets Goodwill, In-Process Research and Development and Other Intangible Assets The fair values of in-process research and development (“IPR&D”) and other identified intangible assets acquired in business combinations are capitalized. We utilize the “income method,” which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs or “replacement costs”, whichever is greater. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each IPR&D project and other identified intangible assets, independently. IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Other identified intangible assets, which include the technology asset acquired as part of the EXINI business combination, AZEDRA product rights intangible and Somerset intangible, are amortized over the relevant estimated useful lives. The IPR&D assets are tested for impairment at least annually or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in our condensed consolidated statements of operations. Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not may one No March 31, 2020 2019. The following tables summarize the activity related to our goodwill and intangible assets (in thousands): Other Intangible Goodwill IPR&D Assets Balance at January 1, 2020 $ 17,847 $ 600 $ 6,223 Amortization expense - - (276 ) Balance at March 31, 2020 $ 17,847 $ 600 $ 5,947 Other Intangible Goodwill IPR&D Assets Balance at January 1, 2019 $ 13,074 $ 600 $ 6,066 Increase related to Somerset acquisition $ 4,773 $ - $ 1,245 Amortization expense - - (260 ) Balance at March 31, 2019 $ 17,847 $ 600 $ 7,051 The following table reflects the components of the finite-lived intangible assets as of March 31, 2020 ( Gross Amount Accumulated Amortization Net Carrying Value Intangible assets - AZEDRA product rights $ 4,900 $ 1,167 $ 3,733 Intangible assets - Somerset 1,245 223 1,022 Intangible assets - EXINI technology 2,120 928 1,192 Total $ 8,265 $ 2,318 $ 5,947

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 . Accrued Expenses The carrying value of our accrued expenses approximates fair value, as it represents amounts that will be satisfied within one March 31, 2020 December 31, 2019 ( March 31, December 31, 2020 2019 Accrued legal and professional fees $ 1,783 $ 1,889 Accrued payroll and related costs 1,241 2,795 Accrued contract manufacturing costs 1,906 5,114 Accrued clinical trial costs 1,805 1,489 Accrued consulting costs 554 1,117 Other 1,094 699 Accrued expenses $ 8,383 $ 13,103

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 . Commitments and Contingencies Consulting Agreement On March 4, 2020, March 27, 2020 May 15, 2020 July 1, 2020, $180,000 not Legal Proceedings We are or may not one Abbreviate d New Drug App lication Litigations RELISTOR Subcutaneous Injection Paragraph IV Certifications - Mylan On or about October 6, 2015, November 20, 2015, December 22, 2015, December 23, 2015, four Paragraph IV Certification – Actavis On or about October 27, 2015, January 5, 2016, January 8, 2016, three District Court Actions Progenics, Salix, Valeant (now Bausch Health Companies Inc., “Bausch”), and Wyeth filed suit against Mylan Pharmaceuticals, Inc. and Mylan Inc. in the District of New Jersey on November 19, 2015 ( 2:15 8180 8,247,425, 8,420,663, 8,552,025, 8,822,490 February 4, 2016, No. 9,180,125. January 4, 2016 ( 2:16 00035 8,247,425, 8,420,663, 8,552,025, 8,822,490 January 25, 2016, No. 9,180,125. September 1, 2017 ( 2:17 06714 No. 9,669,096 September 18, 2017, No. 9,492,445. Progenics, Salix, Bausch, and Wyeth filed suit against Actavis LLC, Actavis, Inc., Actavis Elizabeth LLC, and Allergan PLC fka Actavis PLC in the District of New Jersey on November 30, 2015 ( 2:15 08353 8,247,425, 8,420,663, 8,552,025, 8,822,490 February 18, 2016, No. 9,180,125. February 18, 2016 ( 2:16 00889 8,247,425, 8,420,663, 8,552,025 8,822,490 August 18, 2017 ( 2:17 07206 9,669,096 9,492,445 The 2:15 8180 2:16 00035 2:15 08353 2:16 00889 2:15 08180 May 1, 2018, 8 No. 8,552,025. May 23, 2018, 54 8 ’025 May 16, 2018, 15 8180 17 6714 The 2:17 06714 2:17 07206 2:17 06714 2:17 06714 not 2:15 8180 Settlement Agreement - Actavis On May 25, 2018, No. 2:15 08180 No. 2:17 06714. 30 Under the Actavis Agreement, Plaintiffs grant Actavis a non-exclusive, royalty-free, non-transferable, non-sublicensable, limited license under the Patents-In-Suit to make, import, and sell each of the Actavis Products in the U.S. beginning on the earliest of (a) January 1, 2028; ( 21. 355 5 not 180 180 not not 180 181 third ® third not 180 first third ® first No. 021964 ® ® first third Federal Circuit Appeal On May 25, 2018, On July 9, 2018, July 17, 2018, September 12, 2018. February 8, 2019, April 9, 2019. July 2, 2019. August 6, 2019. February 4, 2020. April 8, 2020, May 8, 2020. April 22, 2020, June 22, 2020. Paragraph IV Certification - Par On or about July 15, 2017, District Court Actions Progenics, Salix, Bausch, and Wyeth filed suit against Par Sterile Products, Par Pharmaceutical, Inc. (“Par Pharmaceutical” and, together with Par Sterile, “Par”), and Endo International plc in the District of New Jersey on August 25, 2017 ( 2:17 06449 8,247,425, 8,420,663, 8,552,025, 8,822,490, 9,180,125, 9,669,096 Progenics, Salix, Bausch, and Wyeth filed suit against Par Sterile Products, Par Pharmaceutical, and Endo International plc in the Southern District of New York on August 25, 2017 ( 1:17 06557 8,247,425, 8,420,663, 8,552,025, 8,822,490, 9,180,125, 9,669,096 November 30, 2017. Settlement Agreement - Par On May 10, 2018, No. 17 06449 The Par Agreement provides for a full settlement and release by both Plaintiffs and Par of all claims that were or could have been asserted in the district court case and all resulting damages or other remedies. Plaintiffs and Par have agreed to and, in fact, filed a Stipulated Consent Judgment and Injunction after the execution of the Par Agreement. Plaintiffs and Par have further acknowledged and agreed that the 30 Under the Par Agreement, Plaintiffs grant Par a non-exclusive, royalty-free, non-transferable, non-sublicensable, limited license under the Patents-In-Suit to make, import, and sell the Par Products in the U.S., or make outside the U.S. solely for importation into the U.S. (the “Par License”) beginning on the earliest of (i) September 30, 2030; ( one hundred eighty-one 181 third 21. 355 5 ® third ® ® third not 180 first not one hundred fifty 150 RELISTOR Tablets - Actavis Paragraph IV Certifications On or about October 24, 2016 October 24, 2017, two District Court Actions Progenics, Salix, Bausch, and Wyeth filed suit against Actavis, Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. in the District of New Jersey on December 6, 2016 ( 2:16 09038 8,420,663, 8,524,276, 8,956,651, 9,180,125, 9,314,461 Progenics, Salix, Bausch, and Wyeth filed suit against Actavis, Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. in the District of New Jersey on December 8, 2017 ( 2:17 12857 9,724,343 9,492,445 The 2:16 09038 2:17 12857 2:16 09038 four May 6, 2019 May 9, 2019. July 17, 2019, No. 8,524,276 No. 209615 may not No. 8,524,276. Progenics, Salix, Bausch, and Wyeth filed suit against Actavis, Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. in the District of New Jersey on June 13, 2019 ( 2:19 13722 No. 10,307,417 2:19 13722 not Federal Circuit Appeal Actavis filed an appeal of the District Court decision with the Court of Appeals for the Federal Circuit on August 13, 2019. February 6, 2020. July 17, 2020. European Opposition Proceedings In addition to the above described ANDA notifications, in October 2015, three EP1615646 September 24, 2015 EP2368553 September 29, 2015 September 30, 2015 EP2368554 September 24, 2015 May 11, 2017, EP2368553 June 28, 2017, EP1615646 July 4, 2017, EP2368554 EP1615646 September 22, 2020. EP2368554 EP2368553, March 9 March 10, 2020, March 9, 2020, November 18, 2020 EP2368554 November 17, 2020 EP2368553. For each of the above-described proceedings, we and Bausch continue to cooperate closely to vigorously defend and enforce RELISTOR intellectual property rights. Pursuant to the RELISTOR license agreement between Progenics and Bausch, Bausch has the first We are or may PSMA- 617 German District Court Litigation We announced a lawsuit and associated worldwide patent ownership dispute based on our claims to certain inventions related to PSMA- 617, On November 8, 2018, 617 617 February 27, 2019, On November 27, 2018, 3038996 A1 14799340.6 18172716.5, 18184296.4, 18203547.7 December 10, 2018, November 27, 2018. December 20, 2018, 15/131,118; 15/805,900; 16/038,729 16/114,988 November 12, 2019, February 21, 2020, December 20, 2018, 16/551,198 16/510,495. March 6, 2020, 16/551,198 16/510,495 On February 27, 2019, €416,000 February 28, 2019, August 6, 2019 first October 1, 2019 January 31, 2020 April 8, 2020. 2020. Third Party Patents Post-Grant Review of U.S. Patent No. 10,112,974 On July 29, 2019 No. 10,112,974 ‘974 ‘974 1 15 31 On August 13, 2019, three 3 not January 29, 2020, ‘974 April 22, 2020 March 13, 2020, 1 5, 7, 9, 13 15 31. April 27, 2020, 6, 8, 10 12 not Litigation Related to the Merger Six lawsuits - four two November 12, 2019 no March 16, 2020 March 19, 2020. On November 22, 2019, Johnson v. Progenics Pharmaceuticals, Inc., et al. No. 1:19 02183, 10 Johnson I March 5, 2020, Johnson I November 25, 2019, second Thompson v. Progenics Pharmaceuticals, Inc., et al. No. 1:19 02194, 10 Thompson March 10, 2020, Thompson November 26, 2019, third Wang v. Progenics Pharmaceuticals, Inc., et al. No. 1:19 10936, 10 Wang December 9, 2019, fourth Michael A. Bernstein IRA v. Progenics Pharmaceuticals, Inc. et al. No. 2:19 21200, 10 Bernstein IRA April 21, 2020 Bernstein IRA May 6, 2020, Bernstein IRA No. 1:20 03521. December 12, 2019, fifth Pill v. Progenics Pharmaceuticals, Inc., et al. No. 1:19 02268, March 10, 2020. December 20, 2019, sixth Hess v. Progenics Pharmaceuticals, Inc., et al. No. 1:19 11683, 10 Hess April 8, 2020, Hess On April 2, 2020, seventh Goldstone v. Progenics Pharmaceuticals, Inc., et al. No. 1:20 02750, 10 Goldstone April 6, 2020, Johnson Johnson v. Progenics Pharmaceuticals, Inc., et al. No. 1:20 02847, 10 Johnson II April 8, 2020, eighth Krueger v. Progenics Pharmaceuticals, Inc., et al. No. 1:20 02913, 10 Krueger The complaints in the Wang Bernstein IRA Hess Goldstone Johnson II Krueger 14 20 17 244.100 14a 9 November 12, 2019 March 16, 2020, March 19, 2020. Goldstone In addition, by letter dated October 14, 2019, 220 may Whistleblower Complaint In July 2019, 806 2002 March 2020, not 180 May 26, 2020.

Note 9 - Operating Leases

Note 9 - Operating Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 9. Operating Leases We lease office and manufacturing space and certain office equipment under noncancelable operating leases. We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not not 9.5% three March 31, 2020 2019, $0.6 $0.5 one 10.5 one five three March 31, 2020 2019, $0.5 The information related to our leases is as follows (in thousands): March 31, December 31, Operating leases 2020 2019 Operating ROU lease assets, noncurrent $ 13,279 $ 13,493 Operating lease liabilities, current 616 599 Operating lease liabilities, noncurrent 14,832 15,005 At March 31, 2020, 2020 (excluding the three months ending March 31, 2020) $ 1,524 2021 2,069 2022 2,213 2023 2,255 2024 2,297 Thereafter 14,510 Total future minimum lease payments 24,868 Less imputed interest (9,420 ) Total lease liabilities $ 15,448

Note 10 - Non-recourse Long-ter

Note 10 - Non-recourse Long-term Debt, Net	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 10 . Non-Recourse Long-Term Debt, Net On November 4, 2016, $50.0 no 9.5%. Under the terms of the loan agreement, payments of interest and principal, if any, are made on the last day of each calendar quarter out of RELISTOR royalty payments received since the immediately-preceding payment date. On each payment date prior to March 31, 2018, March 31, 2018, 50% September 30, 2021, June 30, 2025. In connection with the Royalty-Backed Loan, the debt issuance costs have been recorded as a debt discount in our consolidated balance sheets and are being amortized and recorded as interest expense throughout the life of the loan using the effective interest method. The following tables summarize the components of the Royalty-Backed Loan in our condensed consolidated financial statements for the periods presented (in thousands): March 31, December 31, Condensed Consolidated Balance Sheets 2020 2019 Outstanding principal balance, current portion $ 7,456 $ 7,349 Unamortized debt discount, current portion (216 ) (232 ) Current portion of debt, net $ 7,240 $ 7,117 Outstanding principal balance, long-term portion $ 30,381 $ 32,170 Unamortized debt discount, long-term portion (215 ) (260 ) Long-term debt, net $ 30,166 $ 31,910 Three Months Ended March 31, Condensed Consolidated Statements of Operations 2020 2019 Interest expense $ 939 $ 1,077 Non-cash interest expense 61 71 Total interest expense included in interest (expense) income, net $ 1,000 $ 1,148 As of March 31, 2020, no

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 1 1 . Stockholders ’ Equity Common Stock and Preferred Stock We are authorized to issue 160.0 $0.0013, 20.0 $0.001. Shelf Registration In October 2018, no $250.0 $250.0 $75.0 one In addition, in October 2018 “2018 2018 may $75.0 2018 may ten

Note 12 - Stock-based Compensat

Note 12 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 1 2 . Stock-Based Compensation Equity Incentive Plans We adopted the following stockholder-approved equity incentive plans: ● The 2005 “2005 11,450,000 2005 June 2018 2018 2005 2018 2005 ● The 2018 “2018 4,800,000 2018 March 27, 2028. The stock option plans provide that options may 100% may ten three five Stock Options The following table summarizes stock options activity for the three March 31, 2020 ( Weighted Weighted Average Number Average Remaining of Shares Exercise Price Contractual Life Outstanding at January 1, 2020 6,940 $ 6.35 6.09 Granted 1,233 $ 4.77 Cancelled (1,486 ) $ 6.54 Exercised (36 ) $ 4.52 Outstanding at March 31, 2020 6,651 $ 6.03 7.03 Exercisable at March 31, 2020 4,136 $ 6.61 5.65 Vested and expected to vest at March 31, 2020 5,822 $ 6.17 6.69 The weighted-average fair value of options granted during the three March 31, 2020 2019 $2.65 $2.87 The total intrinsic value (the excess of the market price over the exercise price) was zero March 31, 2020. three March 31, 2020 $6 No three March 31, 2019. Stock-Based Compensation Expense We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 718, Compensation – Stock Compensation three five 718 505 50 50 505, Equity 718, We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted-average assumptions noted in the following table. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, directors, and consultants to hold their stock options) was estimated based on historical rates for three zero not not The following table presents assumptions used in computing the fair value of option grants during the three March 31, 2020 2019. Three Months Ended March 31, 2020 2019 Risk-free interest rate 0.94% 2.62% Expected life (in years) 6.07 6.54 Expected volatility 61% 66% Expected dividend yield -- -- Stock-based compensation expense for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 Research and development expenses $ 487 $ 450 Selling, general and administrative expenses 391 627 Total stock-based compensation expense $ 878 $ 1,077 At March 31, 2020, $4.8 2.8

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Our unaudited condensed consolidated financial statements have been prepared in accordance with applicable presentation requirements, and accordingly, do not not Our unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in our Annual Report on Form 10 December 31, 2019. not
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of Progenics as well as its wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We recognize revenue when our customers obtain control of the promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To account for our revenue arrangements, we perform the following five For contracts determined to be within the scope of ASU 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 606” not The transaction price is then determined and allocated to the identified performance obligations in proportion to their estimated fair value, which requires significant judgment. Variable consideration, which is estimated using the expected value method or the most likely amount method, is included in the transaction price only if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not For arrangements that include development, regulatory or sales milestone payments, we evaluate whether the milestones are probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The following table summarizes our revenue streams from contracts with customers for the three March 31, 2020 2019 Three months ended March 31, 2020 2019 Product sales $ 1,359 $ - Royalty income 4,789 4,161 License and other revenue 100 120 Total revenue $ 6,248 $ 4,281 P roduct sales 60 Royalty income License and o ther revenue not We had receivable contract balances of $6.2 $16.0 March 31, 2020 December 31, 2019, December 31, 2019 Note 5.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Restricted cash included in long-term assets of $2.7 $3.0 March 31, 2020 December 31, 2019, 617
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Our international subsidiaries generally consider their respective local currency to be their functional currency. Assets and liabilities of these international subsidiaries are translated into U.S. dollars at quarter-end exchange rates and revenues and expenses are translated at average exchange rates during the quarter and year-to-date period. Foreign currency translation adjustments for the reported periods are included in accumulated other comprehensive loss in our condensed consolidated statements of comprehensive loss, and the cumulative effect is included in the stockholders’ equity section of our condensed consolidated balance sheets. Realized gains and losses denominated in foreign currencies are recorded in operating expenses in our condensed consolidated statements of operations and were not three March 31, 2020 2019.
Lessee, Leases [Policy Text Block]	Leases We determine whether an arrangement is or contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not not may The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU lease assets are reported in other noncurrent assets on our condensed consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in research and development and selling, general and administrative expenses on our condensed consolidated statements of operations. We do not twelve
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $4.3 $3.8 March 31, 2020 December 31, 2019, March 31, December 31, 2020 2019 Machinery and equipment $ 6,809 $ 5,204 Leasehold improvements 3,621 3,204 Computer equipment 710 691 Furniture and fixtures 908 908 Construction in progress 6,884 5,475 Property and equipment, gross 18,932 15,482 Less - accumulated depreciation (4,259 ) (3,794 ) Property and equipment, net $ 14,673 $ 11,688

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended March 31, 2020 2019 Product sales $ 1,359 $ - Royalty income 4,789 4,161 License and other revenue 100 120 Total revenue $ 6,248 $ 4,281
Property, Plant and Equipment [Table Text Block]	March 31, December 31, 2020 2019 Machinery and equipment $ 6,809 $ 5,204 Leasehold improvements 3,621 3,204 Computer equipment 710 691 Furniture and fixtures 908 908 Construction in progress 6,884 5,475 Property and equipment, gross 18,932 15,482 Less - accumulated depreciation (4,259 ) (3,794 ) Property and equipment, net $ 14,673 $ 11,688

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Weighted-Average Shares Net Loss Outstanding Per Share (Numerator) (Denominator) Amount Three months ended March 31, 2020 Basic and diluted $ (16,801 ) 86,582 $ (0.19 ) Three months ended March 31, 2019 Basic and diluted $ (18,735 ) 84,542 $ (0.22 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2020 2019 Stock options 6,597 6,522 Contingent consideration liability (1) 947 2,565 Total securities excluded 7,544 9,087

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at March 31, 2020 Quoted Prices in Significant Other Significant Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs March 31, 2020 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 20,744 $ 20,744 $ - $ - Total assets $ 20,744 $ 20,744 $ - $ - Liabilities: Contingent consideration liability $ 3,600 $ - $ - $ 3,600 Total liabilities $ 3,600 $ - $ - $ 3,600 Fair Value Measurements at December 31, 2019 Quoted Prices in Active Significant Other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2019 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 35,775 $ 35,775 $ - $ - Total assets $ 35,775 $ 35,775 $ - $ - Liabilities: Contingent consideration liability $ 3,900 $ - $ - $ 3,900 Total liabilities $ 3,900 $ - $ - $ 3,900
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Program Consideration Form of Payment 1095 5,000 Cash or Progenics common stock 1404 9,984 Cash or Progenics common stock or cash in the case of license revenue $ 14,984 Consideration Form of Payment at Progenics' Option $30 million $ 5,000 Cash or Progenics common stock $60 million 5,000 Cash or Progenics common stock $100 million 10,000 Cash or Progenics common stock $250 million 20,000 Cash or Progenics common stock $500 million 30,000 Cash or Progenics common stock $ 70,000
Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]	Fair Value at March 31, 2020 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: 1095 commercialization $ 400 Probability adjusted discounted Probability of success 18% cash flow model Period of expected milestone achievement 2027 Discount rate 10% 1404 commercialization 200 Probability adjusted discounted Probability of success 43% cash flow model Period of expected milestone achievement 2023 - 2035 Discount rate 10% Net sales targets 3,000 Monte-Carlo simulation Probability of success 18% - 90% Discount rate 10% Total $ 3,600 Fair Value at December 31, 2019 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: 1095 commercialization $ 500 Probability adjusted discounted Probability of success 18% cash flow model Period of expected milestone achievement 2026 Discount rate 10% 1404 commercialization 300 Probability adjusted discounted Probability of success 43% cash flow model Period of expected milestone achievement 2022 - 2035 Discount rate 10% Net sales targets 3,100 Monte-Carlo simulation Probability of success 18% - 90% Discount rate 10% Total $ 3,900
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Liability - Contingent Consideration Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 3,900 $ 11,000 Fair value change included in net loss (300 ) 900 Balance at end of period $ 3,600 $ 11,900 Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period $ (300 ) $ 900

Note 5 - Accounts Receivable (T

Note 5 - Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	March 31, December 31, 2020 2019 Royalties $ 4,789 $ 4,304 Product sales, license and other 1,401 11,672 Accounts receivable, net $ 6,190 $ 15,976

Note 6 - Goodwill, In-process_2

Note 6 - Goodwill, In-process Research and Development and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Other Intangible Goodwill IPR&D Assets Balance at January 1, 2020 $ 17,847 $ 600 $ 6,223 Amortization expense - - (276 ) Balance at March 31, 2020 $ 17,847 $ 600 $ 5,947 Other Intangible Goodwill IPR&D Assets Balance at January 1, 2019 $ 13,074 $ 600 $ 6,066 Increase related to Somerset acquisition $ 4,773 $ - $ 1,245 Amortization expense - - (260 ) Balance at March 31, 2019 $ 17,847 $ 600 $ 7,051
Components of Finite Lived Intangible Assets [Table Text Block]	Gross Amount Accumulated Amortization Net Carrying Value Intangible assets - AZEDRA product rights $ 4,900 $ 1,167 $ 3,733 Intangible assets - Somerset 1,245 223 1,022 Intangible assets - EXINI technology 2,120 928 1,192 Total $ 8,265 $ 2,318 $ 5,947

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	March 31, December 31, 2020 2019 Accrued legal and professional fees $ 1,783 $ 1,889 Accrued payroll and related costs 1,241 2,795 Accrued contract manufacturing costs 1,906 5,114 Accrued clinical trial costs 1,805 1,489 Accrued consulting costs 554 1,117 Other 1,094 699 Accrued expenses $ 8,383 $ 13,103

Note 9 - Operating Leases (Tabl

Note 9 - Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	March 31, December 31, Operating leases 2020 2019 Operating ROU lease assets, noncurrent $ 13,279 $ 13,493 Operating lease liabilities, current 616 599 Operating lease liabilities, noncurrent 14,832 15,005
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2020 (excluding the three months ending March 31, 2020) $ 1,524 2021 2,069 2022 2,213 2023 2,255 2024 2,297 Thereafter 14,510 Total future minimum lease payments 24,868 Less imputed interest (9,420 ) Total lease liabilities $ 15,448

Note 10 - Non-recourse Long-t_2

Note 10 - Non-recourse Long-term Debt, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	March 31, December 31, Condensed Consolidated Balance Sheets 2020 2019 Outstanding principal balance, current portion $ 7,456 $ 7,349 Unamortized debt discount, current portion (216 ) (232 ) Current portion of debt, net $ 7,240 $ 7,117 Outstanding principal balance, long-term portion $ 30,381 $ 32,170 Unamortized debt discount, long-term portion (215 ) (260 ) Long-term debt, net $ 30,166 $ 31,910 Three Months Ended March 31, Condensed Consolidated Statements of Operations 2020 2019 Interest expense $ 939 $ 1,077 Non-cash interest expense 61 71 Total interest expense included in interest (expense) income, net $ 1,000 $ 1,148

Note 12 - Stock-based Compens_2

Note 12 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Average Number Average Remaining of Shares Exercise Price Contractual Life Outstanding at January 1, 2020 6,940 $ 6.35 6.09 Granted 1,233 $ 4.77 Cancelled (1,486 ) $ 6.54 Exercised (36 ) $ 4.52 Outstanding at March 31, 2020 6,651 $ 6.03 7.03 Exercisable at March 31, 2020 4,136 $ 6.61 5.65 Vested and expected to vest at March 31, 2020 5,822 $ 6.17 6.69
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2020 2019 Risk-free interest rate 0.94% 2.62% Expected life (in years) 6.07 6.54 Expected volatility 61% 66% Expected dividend yield -- --
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2020 2019 Research and development expenses $ 487 $ 450 Selling, general and administrative expenses 391 627 Total stock-based compensation expense $ 878 $ 1,077

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Apr. 14, 2020	Feb. 20, 2020	Dec. 31, 2019	Oct. 01, 2019	Dec. 31, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 6,248	$ 4,281
Retained Earnings (Accumulated Deficit), Ending Balance	(694,561)				$ (677,760)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	29,531	109,587			42,049		$ 137,686
Cash and Cash Equivalents, Period Increase (Decrease), Total	(12,500)
Accounts Receivable, after Allowance for Credit Loss, Current, Total	6,190				15,976
Restricted Cash and Cash Equivalents, Noncurrent, Total	2,653	1,540			3,016		$ 1,534
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	4,259				$ 3,794
Bridge Loan [Member]
Debt Agreement, Maximum Borrowing Capacity	$ 10,000
Debt Instrument, Interest Rate, Stated Percentage	9.50%
Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 1,359
Pending Merger with Lantheus Holdings, Inc [Member]
Conversion of Stock, Shares Converted per Common Stock Issued and Outstanding (in shares)				0.31		0.2502
Business Combination, Maximum Consideration Paid, Percentage of Total Consideration Received				19.90%
Ownership Percentage After Merger				40.00%		35.00%
Pending Merger with Lantheus Holdings, Inc [Member] | Velan Stockholders [Member] | Subsequent Event [Member]
Liabilities from Reimbursement for Expenses with Stockholders Involvement			$ 1,300

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 6,248	$ 4,281
AZEDRA Product Sales [Member
Revenue	1,359
Royalty [Member]
Revenue	4,789	4,161
License and Other [Member]
Revenue	$ 100	$ 120

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Property and equipment, gross	$ 18,932	$ 15,482
Less - accumulated depreciation	(4,259)	(3,794)
Property and equipment, net	14,673	11,688
Machinery and Equipment [Member]
Property and equipment, gross	6,809	5,204
Leasehold Improvements [Member]
Property and equipment, gross	3,621	3,204
Computer Equipment [Member]
Property and equipment, gross	710	691
Furniture and Fixtures [Member]
Property and equipment, gross	908	908
Construction in Progress [Member]
Property and equipment, gross	$ 6,884	$ 5,475

Note 3 - Net Loss Per Share - C

Note 3 - Net Loss Per Share - Calculations of Net Loss Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic and diluted, net loss attributable to Progenics	$ (16,801)	$ (18,735)
Basic and diluted, weighted average shares outstanding (in shares)	86,582	84,542
Basic and diluted, per share amount (in dollars per share)	$ (0.19)	$ (0.22)

Note 3 - Net Loss Per Share -_2

Note 3 - Net Loss Per Share - Common Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares shares in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Antidilutive securities (in shares)		7,544	9,087
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)		6,597	6,522
Contingent Consideration Liability [Member]
Antidilutive securities (in shares)	[1]	947	2,565
[1]	Calculated as follows: (a) the contingent consideration liability balance divided by (b) the closing stock price of our common stock.

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Business Combination, Contingent Consideration, Liability, Total	$ 3,600		$ 3,900
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(300)	$ 900
AZERDA Commercial Sale Milestone [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 300

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Money market funds	$ 20,744	$ 35,775
Total assets	20,744	35,775
Contingent consideration liability	3,600	3,900
Total liabilities	3,600	3,900
Money market funds	20,744	35,775
Total assets	20,744	35,775
Fair value	3,600	3,900
Total liabilities	3,600	3,900
Fair Value, Inputs, Level 1 [Member]
Money market funds	20,744	35,775
Total assets	20,744	35,775
Contingent consideration liability
Total liabilities
Money market funds	20,744	35,775
Total assets	20,744	35,775
Fair value
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Money market funds
Total assets
Contingent consideration liability
Total liabilities
Money market funds
Total assets
Fair value
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Money market funds
Total assets
Contingent consideration liability	3,600	3,900
Total liabilities	3,600	3,900
Money market funds
Total assets
Fair value	3,600	3,900
Total liabilities	$ 3,600	$ 3,900

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Contingent Consideration Liabilities (Details) $ in Thousands	Mar. 31, 2020USD ($)
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	$ 14,984
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of All Levels of Net Sales [Member]
Contingent Consideration	70,000
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 2 [Member]
Contingent Consideration	5,000
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 3 [Member]
Contingent Consideration	10,000
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 4 [Member]
Contingent Consideration	20,000
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 5 [Member]
Contingent Consideration	30,000
Milestone Payment upon Achievement of Net Sales Level 1 [Member] | Milestone Payment upon Achievement of All Levels of Net Sales [Member]
Contingent Consideration	5,000
The 1095 Program[Member] | Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	5,000
The 1404 Program [Member] | Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	$ 9,984

Note 4 - Fair Value Measureme_6

Note 4 - Fair Value Measurements - Quantitative Information for Fair Value Measurement of Level 3 (Details) $ in Millions	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Fair value	$ 3.6	$ 3.9
MIP-1095 Commercialization [Member]
Fair value	$ 0.4	$ 0.5
MIP-1095 Commercialization [Member] | Measurement Input, Probability of Success [Member]
Measurement input	0.18	0.18
MIP-1095 Commercialization [Member] | Measurement Input, Period of Expected Milestone Achievement [Member]
Measurement input	2,027	2,026
MIP-1095 Commercialization [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.1	0.1
The 1404 Commercialization [Member]
Fair value	$ 0.2	$ 0.3
The 1404 Commercialization [Member] | Measurement Input, Probability of Success [Member]
Measurement input	0.43	0.43
The 1404 Commercialization [Member] | Measurement Input, Period of Expected Milestone Achievement [Member] | Minimum [Member]
Measurement input	2,023	2,022
The 1404 Commercialization [Member] | Measurement Input, Period of Expected Milestone Achievement [Member] | Maximum [Member]
Measurement input	2,035	2,035
The 1404 Commercialization [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.1	0.1
Net sales targets [Member]
Fair value	$ 3	$ 3.1
Net sales targets [Member] | Measurement Input, Probability of Success [Member] | Minimum [Member]
Measurement input	0.18	0.18
Net sales targets [Member] | Measurement Input, Probability of Success [Member] | Maximum [Member]
Measurement input	0.9	0.9
Net sales targets [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.1	0.1

Note 4 - Fair Value Measureme_7

Note 4 - Fair Value Measurements - Summary of Activities in Financial Instruments With Level 3 Inputs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 3.9	$ 11
Fair value change included in net loss	(0.3)	0.9
Balance	3.6	11.9
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$ (0.3)	$ 0.9

Note 5 - Accounts Receivable -

Note 5 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts receivable, net	$ 6,190	$ 15,976
Royalties [Member]
Accounts receivable, net	4,789	4,304
Product Sales, License and Other [Member]
Accounts receivable, net	$ 1,401	$ 11,672

Note 6 - Goodwill, In-process_3

Note 6 - Goodwill, In-process Research and Development and Other Intangible Assets (Details Textual) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Number of Reporting Units	1
Goodwill, Impairment Loss	$ 0	$ 0

Note 6 - Goodwill, In-process_4

Note 6 - Goodwill, In-process Research and Development and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance, Goodwill	$ 17,847	$ 13,074
Amortization expense
Balance, Goodwill	17,847	17,847
Balance, Finite-lived Intangible Assets	5,947
Increase related to Somerset acquisition		4,773
In Process Research and Development [Member]
Balance, Finite-lived Intangible Assets	600	600
Amortization expense, Finite-lived Intangible Assets
Balance, Finite-lived Intangible Assets	600	600
Increase related to Somerset acquisition
Other Intangible Assets [Member]
Balance, Finite-lived Intangible Assets	6,223	6,066
Amortization expense, Finite-lived Intangible Assets	(276)	(260)
Balance, Finite-lived Intangible Assets	$ 5,947	7,051
Increase related to Somerset acquisition		$ 1,245

Note 6 - Goodwill, In-process_5

Note 6 - Goodwill, In-process Research and Development and Other Intangible Assets - Components of Finite-lived Intangible Assets (Details) $ in Thousands	Mar. 31, 2020USD ($)
Gross amount	$ 8,265
Accumulated amortization	2,318
Net carrying value	5,947
AZEDRA Product Rights [Member]
Gross amount	4,900
Accumulated amortization	1,167
Net carrying value	3,733
Somerset [Member]
Gross amount	1,245
Accumulated amortization	223
Net carrying value	1,022
EXINI Technology [Member]
Gross amount	2,120
Accumulated amortization	928
Net carrying value	$ 1,192

Note 7 - Accrued Expenses - Sum

Note 7 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accrued legal and professional fees	$ 1,783	$ 1,889
Accrued payroll and related costs	1,241	2,795
Accrued contract manufacturing costs	1,906	5,114
Accrued clinical trial costs	1,805	1,489
Accrued consulting costs	554	1,117
Other	1,094	699
Accrued expenses	$ 8,383	$ 13,103

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Details Textual)	Mar. 04, 2020USD ($)	Feb. 27, 2019EUR (€)
Deposit With Court as Security [Member] | Pending Litigation [Member]
Estimated Litigation Liability | €		€ 416,000
Patrick Fabbio [Member]
Expected Payment for Consulting Services Upon Consummation of Proposed Merger | $	$ 180,000

Note 9 - Operating Leases (Deta

Note 9 - Operating Leases (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Lease, Weighted Average Discount Rate, Percent	9.50%
Operating Lease, Expense	$ 0.6	$ 0.5
Lessee, Operating Lease, Renewal Term (Year)	5 years
Operating Lease, Payments	$ 0.5	$ 0.5
Minimum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	1 year
Maximum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	10 years 182 days

Note 9 - Operating Leases - Lea

Note 9 - Operating Leases - Lease Information (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Operating ROU lease assets, noncurrent	$ 13,279	$ 13,493
Operating lease liabilities, current	616	599
Operating lease liabilities, noncurrent	$ 14,832	$ 15,005

Note 9 - Operating Leases - Fut

Note 9 - Operating Leases - Future Lease Payments (Details) $ in Thousands	Mar. 31, 2020USD ($)
2020 (excluding the three months ending March 31, 2020)	$ 1,524
2021	2,069
2022	2,213
2023	2,255
2024	2,297
Thereafter	14,510
Total future minimum lease payments	24,868
Less imputed interest	(9,420)
Total lease liabilities	$ 15,448

Note 10 - Non-recourse Long-t_3

Note 10 - Non-recourse Long-term Debt, Net (Details Textual) - Royalty-backed Loan [Member] - USD ($) $ in Millions	Nov. 04, 2016	Mar. 31, 2020
Proceeds from Issuance of Long-term Debt, Total	$ 50
Debt Instrument, Interest Rate, Stated Percentage	9.50%
Percentage of Royalty Payments in Excess of Accrued Loan Interest to be Applied to Principal		50.00%

Note 10 - Non-recourse Long-t_4

Note 10 - Non-recourse Long-term Debt, Net - Summary of Royalty-backed Loan (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Current portion of debt, net	$ 7,240		$ 7,117
Long-term debt, net	30,166		31,910
Royalty-backed Loan [Member]
Outstanding principal balance, current portion	7,456		7,349
Unamortized debt discount, current portion	(216)		(232)
Current portion of debt, net	7,240		7,117
Outstanding principal balance, long-term portion	30,381		32,170
Unamortized debt discount, long-term portion	(215)		(260)
Long-term debt, net	30,166		$ 31,910
Interest expense	939	$ 1,077
Non-cash interest expense	61	71
Total interest expense included in interest (expense) income, net	$ 1,000	$ 1,148

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	1 Months Ended
	Oct. 31, 2018	Mar. 31, 2020	Dec. 31, 2019
Common Stock, Shares Authorized (in shares)		160,000	160,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0013	$ 0.0013
Preferred Stock, Shares Authorized (in shares)		20,000	20,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001	$ 0.001
Replacement Shelf Registration	$ 250
Common Stock Sales Agreement with Agent, Maximum Aggregate Offering Price	$ 75

Note 12 - Stock-based Compens_3

Note 12 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 2.65	$ 2.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 6
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	36,000	0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 4,800
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 292 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years
Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	5 years
The 2005 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	11,450,000
The 2018 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	4,800,000

Note 12 - Stock-based Compens_4

Note 12 - Stock-based Compensation - Summary of Option Activity Under the Plans (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Outstanding, shares (in shares)	6,940,000
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 6.35
Outstanding, Weighted Average Remaining Contractual Life (Year)	7 years 10 days		6 years 32 days
Granted, shares (in shares)	1,233,000
Granted, Weighted Average Exercise Price (in dollars per share)	$ 4.77
Cancelled, shares (in shares)	(1,486,000)
Cancelled, Weighted Average Exercise Price (in dollars per share)	$ 6.54
Exercised, shares (in shares)	(36,000)	0
Exercised, Weighted Average Exercise Price (in dollars per share)	$ 4.52
Outstanding, shares (in shares)	6,651,000		6,940,000
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 6.03		$ 6.35
Exercisable, shares (in shares)	4,136,000
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 6.61
Exercisable, Weighted Average Remaining Contractual Life (Year)	5 years 237 days
Vested and expected to vest, shares (in shares)	5,822,000
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 6.17
Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)	6 years 251 days

Note 12 - Stock-based Compens_5

Note 12 - Stock-based Compensation - Assumptions Used in Computing the Fair Value of Option Grants (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Risk-free interest rate	0.94%	2.62%
Expected life (in years) (Year)	6 years 25 days	6 years 197 days
Expected volatility	61.00%	66.00%
Expected dividend yield	0.00%	0.00%

Note 12 - Stock-based Compens_6

Note 12 - Stock-based Compensation - Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Total compensation expense recognized	$ 878	$ 1,077
Research and Development Expense [Member]
Total compensation expense recognized	487	450
Selling, General and Administrative Expenses [Member]
Total compensation expense recognized	$ 391	$ 627